144 related articles for article (PubMed ID: 12100090)
1. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
Vachharajani NN; Shyu WC; Nichola PS; Boulton DW
Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
Vachharajani NN; Shyu WC; Barbhaiya RH
J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
[TBL] [Abstract][Full Text] [Related]
7. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
Géraud G; Valette C
Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800
[TBL] [Abstract][Full Text] [Related]
8. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Berges A; Walls C; Lener SE; McDonald SA
Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of intranasal sumatriptan.
Fuseau E; Petricoul O; Moore KH; Barrow A; Ibbotson T
Clin Pharmacokinet; 2002; 41(11):801-11. PubMed ID: 12190330
[TBL] [Abstract][Full Text] [Related]
11. Onzetra Xsail--sumatriptan nasal powder.
Med Lett Drugs Ther; 2016 Jul; 58(1499):92-3. PubMed ID: 27403783
[No Abstract] [Full Text] [Related]
12. [Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)].
Scheen AJ
Rev Med Liege; 1997 Sep; 52(9):610-2. PubMed ID: 9441347
[No Abstract] [Full Text] [Related]
13. Parental satisfaction with sumatriptan nasal spray in childhood migraine.
Pakalnis A; Kring D; Paolicchi J
J Child Neurol; 2003 Nov; 18(11):772-5. PubMed ID: 14696905
[TBL] [Abstract][Full Text] [Related]
14. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
[TBL] [Abstract][Full Text] [Related]
15. Zelrix: a novel transdermal formulation of sumatriptan.
Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
Davis GA; Rudy AC; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M
Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403
[TBL] [Abstract][Full Text] [Related]
18. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
[TBL] [Abstract][Full Text] [Related]
19. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
